Trials / Active Not Recruiting
Active Not RecruitingNCT07176130
Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Singapore National Eye Centre · Other Government
- Sex
- All
- Age
- 21 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC).
Detailed description
This is a retrospective, cross-sectional study. In this study, the investigators aim to investigate demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis that presented to the Singapore National Eye Centre (SNEC). Data on demographics, clinical features, diagnosis, investigations, secondary complications, treatment received, and outcomes will be analyzed using statistical software. The results of this study will lead to an improved clinical practice with better treatment selections and an optimized monitoring protocol for follow-up care for patients with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g.,vitreoretinal and uveal lymphoma) and endophthalmitis. This will lead to better clinical outcomes and prevention of serious sight-threatening complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention: Observational Cohort | Not applicable, No intervention. Observational study. |
Timeline
- Start date
- 2025-08-19
- Primary completion
- 2025-09-30
- Completion
- 2025-10-30
- First posted
- 2025-09-16
- Last updated
- 2025-09-16
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT07176130. Inclusion in this directory is not an endorsement.